title: Conventional and tissue-specific inactivation of the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1).
abstract: Mutations in the human 25-hydroxyvitamin-D(3)-1alpha-hydroxylase (CYP27B1) gene cause pseudo vitamin D deficiency rickets (PDDR). The kidney is the main site of expression of the CYP27B1 gene, but expression has been documented in other cell types, including chondrocytes. We engineered a tissue-specific and a conventional knockout of CYP27B1 in mice. The conventional knockout strain reproduced the PDDR phenotype. Homozygote mutant animals were treated with 1,25(OH)(2)D(3) or fed a high-calcium diet (2% calcium, 1.25% phosphate, 20% lactose) for 5 weeks post-weaning. Blood biochemistry revealed that both rescue treatments corrected the hypocalcemia and secondary hyperparathyroidism. Bone histomorphometry confirmed that rickets were cured. The rescue regimen restored the biomechanical properties of the bone tissue. Mice carrying the loxP-bearing allele were bred to transgenic animals expressing the Cre recombinase in chondrocytes under the control of the collagen type II promoter. Genotyping confirmed excision of exon 8 in chondrocytes. Serum biochemistry revealed that mineral ion homeostasis is normal in mutant animals. Preliminary observation of bone tissue from mutant mice did not reveal major changes to the growth plate. Precise histomorphometric analysis will be required to assess the impact of chondrocyte-specific inactivation of CYP27B1 on the maturation and function of growth plate cells in vivo.
authors.affiliation: Genetics Unit, Shriners Hospital for Children, Montreal (Quebec), Canada H3G 1A6. rst-arnaud@shriners.mcgill.ca
authors.forename: René
authors.initials: R
authors.lastname: St-Arnaud
authors.forename: Olivier
authors.initials: O
authors.lastname: Dardenne
authors.forename: Josée
authors.initials: J
authors.lastname: Prud'homme
authors.forename: S Adam
authors.initials: SA
authors.lastname: Hacking
authors.forename: Francis H
authors.initials: FH
authors.lastname: Glorieux
mesh_terms: D015090:25-Hydroxyvitamin D3 1-alpha-Hydroxylase / Q000172:deficiency* / Q000235:genetics; D000818:Animals; D001696:Biomechanical Phenomena; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D002117:Calcitriol / Q000627:therapeutic use*; D002120:Calcium Channel Agonists / Q000627:therapeutic use*; D002136:Calcium, Dietary; D019902:Chondrocytes / Q000502:physiology; D006132:Growth Plate / Q000473:pathology; D006961:Hyperparathyroidism / Q000209:etiology; D006996:Hypocalcemia / Q000209:etiology; D017674:Hypophosphatemia / Q000209:etiology; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D023421:Models, Animal; D010018:Osteomalacia / Q000209:etiology; D012279:Rickets / Q000188:drug therapy* / Q000235:genetics
chemical_list: D002120:Calcium Channel Agonists; D002136:Calcium, Dietary; D015090:25-Hydroxyvitamin D3 1-alpha-Hydroxylase; D002117:Calcitriol